ClinicalTrials.gg
CompletedNCT07083362Updated Apr 28, 2026

Safety, Tolerability and Pharmacokinetic Study of HRS-8829

A Phase 1 interventional study of HRS-8829;Placebo and HRS-8829;Placebo in Acute Ischemia Stroke, sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Ischemia with a site in China — 4 open to participants now, 4 under way, 1 of them phase 3. Ischemia · China.

Enrollment
26th of 34
83 · median 172
Started
2025
with 2 others
Phase 1
5 of 39
none open now
Registered
38th of 39
by date

Among the 39 studies in Ischemia with a site in China, this one is the 26th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 1, and was the 38th registered.

Ischemia

545 studies on the registry are indexed under Ischemia; 72 are open to participants now.

Browse Ischemia studies →

Open to participants now

4 of the 39 studies in Ischemia with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 45 Ischemia studies recruiting now, 35 (78%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Ischemia with a site in China, or all of them as a file.
02

Study summary

This study adopted a single-center, randomized, double-blind, placebo-controlled, dose-escalation design and was divided into three parts: single-dose dose-escalation (SAD) 、 multiple-dose dose-escalation (MAD)、drug-drug interaction(DDI)

03

Conditions studied

  • Acute Ischemia Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects aged 18 to 55 years old
  2. The weight of female subjects was ≥45 kg, that of male subjects was ≥50 kg, and the (BMI) was within the range of 19.0-28.0 kg/m2
  3. The female subjects were not in the pregnancy or lactation period, and the pregnancy examination results before the test were negative; Male or female subjects agreed to take the investigator-approved effective measures during the trial as required by the investigator.
  4. Voluntarily participate in this clinical trial

Exclusion criteria

Exclusion Criteria:

  1. Have any history of allergies
  2. Have had or are currently suffering from diseases of the heart, liver, kidneys, endocrine system, digestive tract, immune system, respiratory system, musculoskeletal system and nervous system, etc
  3. The at lead 12 was abnormal and was judged by the researcher as unsuitable to participate in this study
  4. Those who test positive for any one of surface antigen, antibody, syphilis specific antibody or antigen-antibody during the screening period
  5. Those whose screening period examination results are judged by the research doctor as abnormal and of clinical significance
  6. Those who have used any drugs that inhibit or induce liver enzymes within one month before administration
  7. Those who have used or are currently using any medication within two weeks prior to administration
  8. Those who have received a vaccine within one month prior to screening (except for the influenza vaccine) or plan to receive a vaccine during the trial period
  9. Those who have undergone major surgical operations within the six months prior to screening
  10. Blood donation or loss of more than 400 mL within 3 months prior to screening
  11. Participate in the clinical trial of the drug as a subject and take the trial drug
  12. Consumed more than 14 units of alcohol per week on average within the 3 months prior to screening
  13. Those who smoked more than 5 cigarettes or an equivalent amount of tobacco per day
  14. Those who consumed excessive amounts of tea, coffee, grapefruit/grapefruit juice and/or caffeinated beverages daily
  15. Consume special food within 48 hours before administration
  16. Those with a history of drug abuse
  17. Those who cannot tolerate venipuncture
  18. Those who have special dietary requirements
  19. The researchers believe that the subjects have any other factors that make them unsuitable for participating in this trial
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    Treatment group 1

    Drug: HRS-8829;Placebo

  • Experimental
    Treatment group 2

    Drug: HRS-8829;Placebo

  • Experimental
    Treatment group 3

    Drug: HRS-8829;Placebo

  • Experimental
    Treatment group 4

    Drug: HRS-8829;Placebo

  • Experimental
    Treatment group 5

    Drug: HRS-8829;Edaravone injection

Interventions

  • DrugHRS-8829;Placebo

    Subject will receive HRS-8829 at dose level 1. Subject will receive placebo at dose level 1.

  • DrugHRS-8829;Placebo

    Subject will receive HRS-8829 at dose level 2. Subject will receive placebo at dose level 2.

  • DrugHRS-8829;Placebo

    Subject will receive HRS-8829 at dose level 3. Subject will receive placebo at dose level 3.

  • DrugHRS-8829;Placebo

    Subject will receive HRS-8829 at dose level 4. Subject will receive placebo at dose level 4.

  • DrugHRS-8829;Edaravone injection

    Drug page: Edaravone

    Subject will receive HRS-8829 at dose level 2. Subject will receive edaravone injection at dose level 5.

06

What researchers measure

Primary outcomes

  1. The incidence and severity of adverse events

    Time frame: From ICF signing date to Day8 after single administration

  2. The incidence and severity of adverse events

    Time frame: From ICF signing date to Day15 after multiple administrations

  3. The Incidence and severity of adverse events

    Time frame: from the date of ICF signing to the 21st day after DDI administration

Secondary outcomes

  1. Maximum observed concentration of HRS-8829 and its metabolite in plasma (Cmax)

    Time frame: 0 hour to 48 hour after single administration

  2. Area under the serum concentration time curve (AUC) of HRS-8829 and its metabolite in plasma

    Time frame: 0 hour to 48 hour after single administration

  3. Time to maximum observed concentration (Tmax) of HRS-8829 and its metabolite in plasma

    Time frame: 0 hour to 48 hour after single administration

  4. Half-life (T1/2) of HRS-8829 and its metabolite in plasma

    Time frame: 0 hour to 48 hour after single administration

  5. Clearance (CL) of HRS-8829 and its metabolite in plasma

    Time frame: 0 hour to 48 hour after single administration

  6. Volume of distribution (Vz) of HRS-8829 and its metabolite in plasma

    Time frame: 0 hour to 48 hour after single administration

  7. Cumulative amount excreted (Ae0-t) of HRS-8829 and its metabolite in urine

    Time frame: 0 hour to 48 hour after single administration

  8. Cumulative excretion fraction (Fe0-t) of HRS-8829 and its metabolite in urine

    Time frame: 0 hour to 48 hour after single administration

  9. Renal clearance (CLr) of HRS-8829 and its metabolite in urine

    Time frame: 0 hour to 48 hour after single administration

  10. Maximum observed concentration at steady-state of HRS-8829 and its metabolite in plasma (Cmax)

    Time frame: Day1 to Day15 after multiple administrations

  11. Area under the serum concentration time curve (AUC) at steady-state of HRS-8829 and its metabolite in plasma

    Time frame: Day1 to Day15 after multiple administrations

  12. Time to maximum observed concentration (Tmax) of HRS-8829 and its metabolite in plasma

    Time frame: Day1 to Day15 after multiple administrations

  13. Half-life (T1/2) of HRS-8829 and its metabolite in plasma

    Time frame: Day1 to Day15 after multiple administrations

  14. Clearance (CL) of HRS-8829 and its metabolite in plasma

    Time frame: Day1 to Day15 after multiple administrations

  15. Volume of distribution (Vz) of HRS-8829 and its metabolite in plasm

    Time frame: Day1 to Day15 after multiple administrations

  16. Maximum observed concentration at steady-state of HRS-8829 and its metabolites M01 and edaravone

    Time frame: Day1 to Day 16 after DDI study single-dose, plasma administrations

  17. Area under the serum concentration time curve (AUC) at steady-state of HRS-8829 and its metabolites M01 and edaravone

    Time frame: Day1 to Day16 after DDI study single-dose, plasma administrations

  18. Time to maximum observed concentration (Tmax) of HRS-8829 and its metabolites M01 and edaravone

    Time frame: Day1 to Day16 after DDI study single-dose, plasma administrations

  19. Half-life (T1/2) of HRS-8829 and its metabolites M01 and edaravone

    Time frame: Day1 to Day16 after DDI study single-dose, plasma administrations

  20. Clearance (CL) of HRS-8829 and its metabolites M01 and edaravone

    Time frame: Day1 to Day16 after DDI study single-dose, plasma administrations

  21. Volume of distribution (Vz) of HRS-8829 and its metabolites M01 and edaravone

    Time frame: Day1 to Day16 after DDI study single-dose, plasma administrations

  22. Area under the serum concentration time curve (AUC) at steady-state of HRS-8829 and its metabolites M01 and edaravone

    Time frame: Day1 to Day16 after DDI study multiple-dose, plasma administrations

  23. Time to maximum observed concentration (Tmax) of HRS-8829 and its metabolites M01 and edaravone

    Time frame: Day1 to Day16 after DDI study multiple-dose, plasma administrations

  24. Half-life (T1/2) of HRS-8829 and its metabolites M01 and edaravone

    Time frame: Day1 to Day16 after DDI study multiple-dose, plasma administrations

  25. Volume of distribution (Vz) of HRS-8829 and its metabolites M01 and edaravone

    Time frame: Day1 to Day16 after DDI study multiple-dose, plasma administrations

07

Study locations

1 site
  • Beijing Anzhen Hospital, Capital Medical University
    Beijing, Beijing Municipality 100029, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Jan 2026, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2025
First posted
Jul 24, 2025
StartActual
Aug 6, 2025
Primary completionActual
Jan 12, 2026
CompletionActual
Jan 12, 2026
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07083362
Responsible party
Sponsor
First posted
Jul 24, 2025
Start date
Aug 6, 2025
Primary completion
Jan 12, 2026
Completion
Jan 12, 2026
Last update
Apr 28, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edaravone

Start the discussion